Miracle Mile Advisors LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 445.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,986 shares of the company’s stock after buying an additional 32,659 shares during the quarter. Miracle Mile Advisors LLC’s holdings in AstraZeneca were worth $2,620,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in AZN. Martin Investment Management LLC boosted its position in AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Nordea Investment Management AB acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $754,000. Integrated Advisors Network LLC raised its holdings in shares of AstraZeneca by 46.6% during the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the period. Creative Planning lifted its position in AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares in the last quarter. Finally, Soros Fund Management LLC boosted its holdings in AstraZeneca by 8.2% in the 3rd quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock worth $206,677,000 after acquiring an additional 201,233 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.
Analyst Ratings Changes
A number of analysts have recently issued reports on AZN shares. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca has an average rating of “Buy” and an average price target of $89.75.
AstraZeneca Trading Down 1.9 %
AZN opened at $65.73 on Tuesday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock has a market capitalization of $203.80 billion, a PE ratio of 31.45, a P/E/G ratio of 1.19 and a beta of 0.46. The firm’s fifty day moving average price is $66.00 and its 200 day moving average price is $74.78.
AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.87 EPS. As a group, research analysts expect that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
- Five stocks we like better than AstraZeneca
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How to Effectively Use the MarketBeat Ratings Screener
- Delta Can Fly to New Highs in 2025; Here’s Why
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.